Italy · Research startup
Italy · Sibylla Biotech
Sibylla Biotech is a preclinical-stage biotechnology company based in Italy, focused on drug discovery for currently incurable diseases.
Funding reportedLast round: Series A
Follow Sibylla Biotech and see its new rounds in your feed.Start following
About Sibylla Biotech
Sibylla Biotech is a preclinical-stage biotechnology company based in Italy, focused on drug discovery for currently incurable diseases.
Founded as a spin-off from the Italian National Institute for Nuclear Physics and local universities, the company has developed a unique platform that utilizes computer simulations and AI to create small molecule degraders. This innovative approach, known as Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT), allows Sibylla to target previously inaccessible protein structures, enabling the design of therapeutic solutions across various therapeutic areas, including oncology and viral infections. The company has gained recognition for its contributions to the life sciences field, being named one of the best start-ups globally by *Nature*. Sibylla secured €23 million in Series A financing to advance its proprietary pipeline and offers collaborative partnerships to pharmaceutical companies for drug discovery and preclinical studies. With a mission to treat diseases deemed untreatable, Sibylla Biotech is positioned to make significant advancements in the targeted protein degradation field.
What company datasets say Sibylla Biotech raised
Funding, as reported
Founders and team
From Sibylla Biotech's own website: 6 founders, 24 on the team.
- Usman AzamCEO
- Gianluca FuggettaCFO
- Alexandros PatsilinakosHead of Medicinal Chemistry Discovery Lab
- Enrica ColasurdoHead of Computational Lab
- Gianluca PapeoHead of Medicinal Chemistry Development Lab
- Serena BonifatiHead of Assay Biology
- Simone LanfrediniHead of In vivo Pharmacology
- Alessandro GalbiatiDirector of Biology
- Carmine VarricchioPrincipal Scientist
- Cassiano LanginiSenior Scientist
- Ciro SpedaliereBoard member
- Dieter WeinandChairman
- Fabiana RussoSenior Principal Scientist
- Giovanni RizzoBoard member
- Giulia FrapportiSenior Scientist
- Laura RaggiSenior Scientist
- Leda BenchevaSenior Principal Scientist
- Marianne BjordalBoard member
And 6 more on the team.
On 5 portfolio pages
Investors who name them
Each firm lists Sibylla Biotech on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
health carefolding intermediatesco-translational foldingbiotechnology researchprotein folding simulationstargeted protein inactivationneurodegenerative diseasesprotein misfoldinginformation technology & servicesbiotech collaborationscomputational drug designhospital & health carecomputational biophysicsoncology therapeuticsmedicalphysics-based modeling
Built with from their website
Google Tag ManagerWordPress.orgYouTubeGoogle WorkspaceViewport MetaApple Business ManagerGoogle MeetPriority HintsGoogle Font APIFitVids.JS
+8 more
CookiebotMySQLPrimeNGMobile FriendlyOpen GraphjQueryRSSYoast SEO
- Sector
- Research
- Industry code
- NAICS 541714, SIC 2834
- Region
- Lombardia
- Revenue
- 4.1M a year, as listed
- Full record
- Every detail in the company directory
Research in Italy
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Sibylla Biotech in front of investors. Or tell us what we have wrong.